NEW DELHI: Administrators of Pfizer, one of the world’s premier biopharmaceutical companies, on Tuesday, October 27, expressed calculated optimism over the likelihood of supplying a COVID-19 vaccine in 2020 as the company reported lower profits due to disturbance in healthcare that affected the drug demand greatly.
Dr Albert Bourlo, Chief Executive of Pfizer, said that the drug jumbo will possibly supply around 40 million doses in the United States in 2020 if the medical testing of the vaccine progresses as expected and is officially approved.
Pfizer has signed a contract with the US government to provide 40 million doses by the end of year 2020 and 100 million by March 2021. Nevertheless, Dr Albert added that the company still had not achieved the essential benchmarks in examining the vaccine efficiency. He also said that he is not confidently optimistic but cautiously optimistic that the vaccine will work.